160 related articles for article (PubMed ID: 4040447)
1. Changes in fibrinolytic activity during the course of a single hemodialysis session.
Kurz H; Lerner RG; Weseley S; Nelson JC
Clin Nephrol; 1985 Jul; 24(1):1-4. PubMed ID: 4040447
[TBL] [Abstract][Full Text] [Related]
2. Enhanced fibrinolytic activity during the course of hemodialysis.
Nakamura Y; Tomura S; Tachibana K; Chida Y; Marumo F
Clin Nephrol; 1992 Aug; 38(2):90-6. PubMed ID: 1387598
[TBL] [Abstract][Full Text] [Related]
3. Studies of fibrinolytic activity of uremic and longterm hemodialytic patients with special reference to fibrinolytic inhibitor.
Homma T; Ichikawa T
Biochem Exp Biol; 1979; 15(3):229-36. PubMed ID: 122165
[TBL] [Abstract][Full Text] [Related]
4. Fibrinolytic activity during hemodialysis: a biocompatibility-related phenomenon.
Martin-Malo A; Velasco F; Rojas R; Castillo D; Rodriguez M; Torres A; Aljama P
Kidney Int Suppl; 1993 Jun; 41():S213-6. PubMed ID: 8320924
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress effects fibrinolytic system in dialysis uraemic patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2006; 117(5):517-22. PubMed ID: 15964061
[TBL] [Abstract][Full Text] [Related]
6. [Tissue plasminogen activator antigen (t-PA Ag) and tissue plasminogen activator inhibitor (PAI-1) in the course of hemodialysis in patients with chronic renal failure].
Piatkowska M; Kotschy M; Nartowicz E; Rajewski W
Pol Merkur Lekarski; 1997 Jan; 2(9):205-7. PubMed ID: 10907030
[TBL] [Abstract][Full Text] [Related]
7. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495
[TBL] [Abstract][Full Text] [Related]
8. Platelet (dys)function and plasma plasminogen levels in hemodialysis patients.
Salobir B; Sabovic M; Zupan IP; Ponikvar JB
Ther Apher Dial; 2008 Apr; 12(2):133-6. PubMed ID: 18387161
[TBL] [Abstract][Full Text] [Related]
9. Fibrinolytic activators and inhibitors in terminal renal insufficiency and in anephric patients.
Brommer EJ; Schicht I; Wijngaards G; Verheijen JH; Rijken DC
Thromb Haemost; 1984 Dec; 52(3):311-4. PubMed ID: 6085194
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolytic abnormalities following liver transplantation in patients with fulminant hepatic failure.
Pernambuco JR; Langley PG; Hughes RD; Izumi S; Williams R
Eur J Gastroenterol Hepatol; 1995 Feb; 7(2):155-9. PubMed ID: 7536112
[TBL] [Abstract][Full Text] [Related]
11. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
[TBL] [Abstract][Full Text] [Related]
12. Changes in pericardial morphology and fibrinolytic activity during cardiopulmonary bypass.
Nkere UU; Whawell SA; Thompson EM; Thompson JN; Taylor KM
J Thorac Cardiovasc Surg; 1993 Aug; 106(2):339-45. PubMed ID: 8341074
[TBL] [Abstract][Full Text] [Related]
13. Coagulation and fibrinolysis factors in dialysis patients with and without ischemic heart disease.
Oda H; Ohno M; Ohashi H
Adv Perit Dial; 2000; 16():152-5. PubMed ID: 11045282
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
15. Plasma fibrinolytic activity in patients undergoing major abdominal surgery.
Mellbring G; Dahlgren S; Wiman B
Acta Chir Scand; 1985; 151(2):109-14. PubMed ID: 3873768
[TBL] [Abstract][Full Text] [Related]
16. Tissue plasminogen activator as a hemodialysis catheter locking solution.
McGill RL; Spero JA; Sysak JC; Sandroni SE; Marcus RJ
Hemodial Int; 2008 Jul; 12(3):348-51. PubMed ID: 18638092
[TBL] [Abstract][Full Text] [Related]
17. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis.
Vaziri ND; Gonzales EC; Wang J; Said S
Am J Kidney Dis; 1994 Jun; 23(6):828-35. PubMed ID: 8203365
[TBL] [Abstract][Full Text] [Related]
18. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
[TBL] [Abstract][Full Text] [Related]
19. Elevated homocysteine levels in patients with end-stage renal disease.
Nair AP; Nemirovsky D; Kim M; Geer EB; Farkouh ME; Winston J; Halperin JL; Robbins MJ
Mt Sinai J Med; 2005 Nov; 72(6):365-73. PubMed ID: 16358160
[TBL] [Abstract][Full Text] [Related]
20. Fibrinolytic activity in blood and lungs of rats treated with monocrotaline pyrrole.
Schultze AE; Roth RA
Toxicol Appl Pharmacol; 1993 Jul; 121(1):129-37. PubMed ID: 7687795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
